SCHEDULE: Franklin Resources Amends 16% Stake in Achieve Life Sciences

Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. have filed an amendment to their beneficial ownership of 16.0% in Achieve Life Sciences, Inc., including shares issuable from warrants.

Summary

• Franklin Resources, Inc. and its subsidiary Franklin Advisers, Inc. reported beneficial ownership of 8,640,039 shares of Achieve Life Sciences, Inc. Common Stock.
• This represents 16.0% of the total class of securities.
• Franklin Advisers, Inc. holds sole voting and dispositive power over all 8,640,039 shares.
• The reported shares include 4,181,025 shares of Common Stock issuable upon the exercise of warrants.
• Two specific funds, Franklin Biotechnology Discovery Fund (a series of Franklin Strategic Series) and Franklin Biotechnology Discovery Fund (a sub-fund of Franklin Templeton Investment Funds), hold significant interests of 8.3% (4,476,098 shares) and 7.7% (4,163,770 shares) respectively.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant, ongoing institutional ownership stake, including potential future shares from warrants. It does not indicate a change in strategy or performance, but the continued large stake by a major investor is generally viewed as a positive signal of confidence.

Positives

• A significant institutional investor, Franklin Resources, maintains a substantial 16.0% stake in Achieve Life Sciences, Inc., which can be interpreted as a signal of continued confidence or a long-term investment strategy.
• The inclusion of 4,181,025 shares issuable from warrants indicates a potential for future increase in direct ownership by the investor.

Negatives

• No specific negative financial or operational information regarding Achieve Life Sciences, Inc. is disclosed in this beneficial ownership filing.

Risks

• The filing itself does not detail specific operational or financial risks of Achieve Life Sciences, Inc.; it focuses solely on beneficial ownership.
• Potential dilution risk for existing shareholders if the 4,181,025 warrants are exercised, as this would increase the total outstanding shares of the company.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investor's stake in a biotechnology company. Such investments are common in the biotech sector, which often requires substantial capital and long-term investment horizons due to the nature of drug development and clinical trials. The continued large stake by Franklin Resources, a major asset manager, suggests a long-term view on the sector or the specific company.

Comparison to Industry Standards

• Franklin Resources, Inc. is a major global investment management organization. Its significant stake (16.0%) in Achieve Life Sciences, Inc. is a notable position for an institutional investor in a biotechnology company, often indicating a strategic or long-term holding.
• The beneficial ownership structure, involving a parent holding company (Franklin Resources, Inc.) and its investment adviser subsidiary (Franklin Advisers, Inc.), is a standard and common practice for large asset managers to manage their various investment mandates.
• The disclosure of specific underlying funds, such as Franklin Biotechnology Discovery Fund, holding substantial portions of the stake is typical for transparency in institutional ownership, allowing for a clearer understanding of the investment vehicle's focus.

Related Party Transactions

• The filing details the beneficial ownership structure involving Franklin Resources, Inc. as the parent holding company and Franklin Advisers, Inc. as its investment management subsidiary.
• Charles B. Johnson and Rupert H. Johnson, Jr., identified as principal shareholders of Franklin Resources, Inc., are also listed as reporting persons, though they disclaim pecuniary interest in the reported securities.
• The ownership is held on behalf of clients of Investment Management Subsidiaries, including specific investment funds like Franklin Biotechnology Discovery Fund.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity. The potential exercise of warrants could lead to dilution of existing shares.
• Company Management: Awareness of a large, stable institutional shareholder can influence strategic decisions and corporate governance considerations.

Key Dates

Keywords

Achieve Life Sciences, Franklin Resources, Franklin Advisers, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Investment Fund, Warrants